Imunon, Inc.
IMNNHealthcare|Biotechnology|US
$0.84
-0.06 (-6.16%)
DCF Value
$3.07
Tangible Book / Share
$0.80
Cash / Share
$1.31
Financials
Financial Snapshot
Market Cap
$4.7M
Enterprise Value
$5.7M
Revenue (TTM)
$0.00
Net Income (TTM)
-$14.7M
Cash & Investments
$6.9M
Net Cash
-$980.9K
Free Cash Flow (TTM)
-$4.07B
Operating CF (TTM)
-$4.00B
Debt/Equity
1.87
Cash Runway & Burn Rate
Cash on Hand
$6.9M
Quarterly Burn
$1.00B
Monthly Burn
$333.6M
Est. Runway
~0.0 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $4.3M | $24.2M | $27.6M | $14.9M | $17.2M | $49.4M | $32.7M | $15.7M | $5.9M | $8.8M | $6.9M | |
| Operating Cash Flow | -$18.4M | -$16.6M | -$7.0M | -$20.3M | -$15.6M | -$16.2M | -$23.1M | -$19.0M | -$18.9M | -$13.9M | -$4.00B | |
| Free Cash Flow | -$18.4M | -$16.7M | -$7.2M | -$20.6M | -$15.6M | -$16.5M | -$23.4M | -$19.5M | -$18.9M | -$14.2M | -$4.07B | |
| Capital Expenditure | -$62.5K | -$38.6K | -$138.4K | -$349.2K | -$19.1K | -$311.6K | -$267.8K | -$451.8K | -$29.5K | -$280.6K | -$69.1M | |
| Financing Cash Flow | $2.7M | $36.5M | $10.6M | $7.8M | $18.0M | $54.8M | $6.7M | -$3.6M | $9.1M | $17.1M | $11.02B |
R&D Spending
R&D (TTM)
$8.2M
R&D Intensity
—
R&D Growth vs Prior
+5.3%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $14.6M | $13.1M | $11.9M | $13.1M | $11.3M | $10.6M | $11.7M | $11.3M | $11.6M | $7.8M | $8.2M | |
| R&D % of Revenue | 2924.6% | 2615.7% | 2373.1% | 2613.1% | 2269.0% | 2123.9% | 2346.7% | — | — | — | — | |
| SG&A | $6.5M | $5.9M | $9.7M | $8.0M | $7.6M | $10.9M | $13.7M | $9.7M | $7.5M | $6.9M | $1.97B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $166.5K | |
| Gross Profit | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $0.00 | $0.00 | $0.00 | -$166.5K | |
| R&D | $14.6M | $13.1M | $11.9M | $13.1M | $11.3M | $10.6M | $11.7M | $11.3M | $11.6M | $7.8M | $8.2M | |
| SG&A | $6.5M | $5.9M | $9.7M | $8.0M | $7.6M | $10.9M | $13.7M | $9.7M | $7.5M | $6.9M | $1.97B | |
| Operating Income | -$20.6M | -$18.5M | -$21.1M | -$20.6M | -$18.5M | -$21.0M | -$24.9M | -$21.0M | -$19.1M | -$14.7M | -$14.8M | |
| Interest Expense | $723.0K | $91.8K | $712.0K | $1.4M | $1.3M | $569.9K | $5.0M | $197.1K | $0.00 | $0.00 | $77.3K | |
| Pretax Income | -$22.1M | -$20.4M | -$22.3M | -$18.7M | -$23.3M | -$22.2M | -$37.5M | -$20.8M | -$18.6M | -$14.5M | -$14.7M | |
| Net Income | -$22.1M | -$20.4M | -$11.9M | -$16.9M | -$21.5M | -$20.8M | -$35.9M | -$19.5M | -$18.6M | -$14.5M | -$14.7M | |
| EPS (Diluted) | -2328.26 | -532.22 | -132.23 | -151.01 | -131.51 | -748.77 | -65.55 | -28.14 | -21.10 | -6.83 | -4.53 | |
| EBITDA | -$20.3M | -$19.8M | -$21.2M | -$16.6M | -$21.3M | -$20.9M | -$31.7M | -$19.9M | -$17.9M | -$13.8M | -$14.0M | |
| Shares Out. (M) | 0.01 | 0.04 | 0.09 | 0.11 | 0.16 | 0.03 | 0.55 | 0.69 | 0.88 | 2.12 | 5.23 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.6M | $11.4M | $13.4M | $6.9M | $17.2M | $19.6M | $11.5M | $5.8M | $5.9M | $8.8M | $6.9M | |
| Short-Term Investments | $1.7M | $12.7M | $14.3M | $8.0M | $0.00 | $29.8M | $21.3M | $9.9M | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $4.5M | $24.3M | $28.1M | $16.2M | $18.8M | $51.9M | $36.8M | $18.2M | $8.0M | $10.7M | $8.7M | |
| Total Assets | $30.8M | $47.5M | $46.9M | $38.3M | $37.5M | $74.0M | $44.0M | $21.9M | $9.7M | $12.3M | $15.0M | |
| Total Current Liabilities | $8.4M | $6.2M | $6.1M | $7.9M | $6.8M | $6.8M | $10.0M | $7.4M | $4.8M | $4.6M | $4.8M | |
| Long-Term Debt | $0.00 | $0.00 | $9.4M | $8.0M | $3.9M | $5.9M | $4.6M | $0.00 | $0.00 | $602.0K | $5.5M | |
| Total Liabilities | $24.1M | $20.8M | $26.0M | $23.7M | $18.9M | $18.3M | $14.6M | $8.5M | $5.5M | $5.2M | $10.8M | |
| Stockholders' Equity | $6.7M | $26.7M | $20.9M | $14.6M | $18.6M | $55.8M | $29.3M | $13.4M | $4.2M | $7.1M | $4.2M | |
| Retained Earnings | -$241.4M | -$261.8M | -$273.7M | -$290.5M | -$312.0M | -$332.8M | -$368.7M | -$388.2M | -$406.8M | -$421.3M | -$428.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.4M | -$16.6M | -$7.0M | -$20.3M | -$15.6M | -$16.2M | -$23.1M | -$19.0M | -$18.9M | -$13.9M | -$4.00B | |
| Capital Expenditure | -$62.5K | -$38.6K | -$138.4K | -$349.2K | -$19.1K | -$311.6K | -$267.8K | -$451.8K | -$29.5K | -$280.6K | -$69.1M | |
| Free Cash Flow | -$18.4M | -$16.7M | -$7.2M | -$20.6M | -$15.6M | -$16.5M | -$23.4M | -$19.5M | -$18.9M | -$14.2M | -$4.07B | |
| Investing Cash Flow | $9.1M | -$11.0M | -$1.6M | $5.9M | $7.9M | -$30.1M | $8.3M | $11.0M | $9.8M | -$280.6K | -$69.1M | |
| Financing Cash Flow | $2.7M | $36.5M | $10.6M | $7.8M | $18.0M | $54.8M | $6.7M | -$3.6M | $9.1M | $17.1M | $11.02B | |
| Issuance of Stock | $6.8M | $17.9M | $858.5K | $7.8M | $22.8M | $52.7M | $6.7M | $2.8M | $9.1M | $17.1M | $854.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$4.1M | -$2.6M | $9.7M | $0.00 | -$5.2M | $566.0K | $0.00 | -$6.4M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.5M | $1.1M | $4.6M | $2.3M | $1.9M | $3.8M | $2.7M | $759.0K | $477.3K | $127.4K | $93.3M | |
| Net Change in Cash | -$6.6M | $8.8M | $1.9M | -$6.5M | $10.3M | $8.4M | -$8.1M | -$11.7M | $34.2K | $2.9M | $6.95B |
Dilution Tracker
Shares outstanding grew 1199.6% over 5 years — significant dilution
Shares Outstanding
6M
5-Year Share Growth
+1199.6%
Stock Issuance (TTM)
$854.9M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.04 | 0.09 | 0.11 | 0.16 | 0.03 | 0.55 | 0.69 | 0.88 | 2.12 | 5.23 | |
| Change vs Prior % | — | 311.4% | 130.5% | 24.2% | 46.4% | -83.0% | 1874.4% | 26.6% | 27.2% | 140.6% | 146.5% | |
| Stock Issuance | $6.8M | $17.9M | $858.5K | $7.8M | $22.8M | $52.7M | $6.7M | $2.8M | $9.1M | $17.1M | $854.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.5M | $1.1M | $4.6M | $2.3M | $1.9M | $3.8M | $2.7M | $759.0K | $477.3K | $127.4K | $93.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | |
| Operating Margin % | -4130.0% | -3693.7% | -4213.0% | -4113.1% | -3697.3% | -4201.4% | -4984.3% | — | — | — | — | |
| Net Margin % | -4410.7% | -4080.4% | -2376.7% | -3370.3% | -4296.7% | -4153.9% | -7179.6% | — | — | — | — | |
| EBITDA Margin % | -4061.6% | -3951.5% | -4246.7% | -3310.6% | -4259.1% | -4176.0% | -6341.0% | — | — | — | — | |
| FCF Margin % | -3688.4% | -3336.1% | -1436.0% | -4121.6% | -3127.6% | -3307.0% | -4672.9% | — | — | — | — | |
| ROE % | -327.9% | -76.4% | -57.0% | -115.7% | -115.4% | -37.2% | -122.4% | -145.8% | -438.7% | -205.3% | -314.9% | |
| ROA % | -71.5% | -42.9% | -25.4% | -44.0% | -57.2% | -28.0% | -81.6% | -89.0% | -191.6% | -118.0% | -98.2% | |
| ROIC % | -82.6% | -44.7% | -27.5% | -56.9% | -52.7% | -29.0% | -67.1% | -131.5% | -355.4% | -181.5% | -122.2% | |
| R&D / Revenue % | 2924.6% | 2615.7% | 2373.1% | 2613.1% | 2269.0% | 2123.9% | 2346.7% | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | |
| Operating Income | 0.9% | 10.6% | -14.1% | 2.4% | 10.1% | -13.6% | -18.6% | 15.6% | 9.0% | 23.4% | |
| Net Income | 1.8% | 7.5% | 41.8% | -41.8% | -27.5% | 3.3% | -72.8% | 45.6% | 4.6% | 22.2% | |
| EPS (Diluted) | 17.5% | 77.1% | 75.2% | -14.2% | 12.9% | -469.4% | 91.2% | 57.1% | 25.0% | 67.6% | |
| Operating Cash Flow | 11.8% | 9.5% | 57.7% | -187.7% | 22.9% | -3.9% | -42.4% | 17.6% | 0.9% | 26.3% | |
| Free Cash Flow | 11.9% | 9.5% | 57.0% | -187.0% | 24.1% | -5.7% | -41.3% | 16.7% | 3.0% | 24.9% | |
| R&D Expense | -0.3% | -10.6% | -9.3% | 10.1% | -13.2% | -6.4% | 10.5% | -3.8% | 3.1% | -33.2% | |
| SG&A Expense | -2.4% | -9.8% | 64.7% | -17.5% | -4.5% | 42.5% | 25.7% | -28.8% | -23.1% | -8.3% | |
| Total Assets | -37.1% | 54.0% | -1.4% | -18.3% | -2.0% | 97.3% | -40.6% | -50.2% | -55.7% | 26.5% | |
| Book Value / Share | -72.3% | -3.5% | -66.1% | -43.8% | -12.7% | 1665.7% | -97.3% | -64.0% | -75.1% | -30.9% | |
| Debt | -60.1% | -100.0% | 0.0% | 20.4% | -45.3% | 7.1% | -5.5% | -74.1% | -29.9% | -11.5% | |
| Diluted Shares | 19.0% | 311.4% | 130.5% | 24.2% | 46.4% | -83.0% | 1874.4% | 26.6% | 27.2% | 140.6% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High6.74 / 47.01 / 85.87
P/B1.06
10Y Low / Med / High0.06 / 1.33 / 2.96
EV/EBITDAAt Loss
EV/Revenue0.00
10Y Low / Med / High11.73 / 30.25 / 94.79
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$3.07
Tangible Book / Share
$0.80
Cash / Share
$1.31
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.41 | -1.13 | -2.40 | -2.55 | -1.21 | -0.16 | -0.31 | -0.36 | -0.68 | -0.56 | -0.19 | |
| P/S Ratio | 17.91 | 47.01 | 57.02 | 85.87 | 52.19 | 6.74 | 22.18 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 1.33 | 0.88 | 1.37 | 2.95 | 1.40 | 0.06 | 0.38 | 0.53 | 2.96 | 1.15 | 1.06 | |
| EV/EBITDA | -0.44 | -0.61 | -1.16 | -2.86 | -0.71 | 0.46 | -0.18 | -0.14 | -0.44 | -0.02 | -0.41 | |
| EV/Revenue | 17.78 | 24.13 | 49.15 | 94.79 | 30.25 | -19.16 | 11.73 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-42.66
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $3.9M | $5.4M | $11.5M |
| Net Income | -$4.9M | -$3.9M | -$3.1M |
| EPS | $-2.36 | $-1.82 | $-1.36 |
| # Analysts (EPS) | 3 | 3 | 3 |